본문 바로가기

EU · EudraLex Vol.4

EU GMP Annex 1 9.36

9. Environmental & process monitoring › Aseptic process simulation (APS) (also known as media fill)

조항 원문

In developing the APS plan, consideration should be given to the following:

i. Identification of worst case conditions covering the relevant variables, such as container size and line speed, and their impact on the process. The outcome of the assessment should justify the variables selected.

ii. Determining the representative sizes of container/closure combinations to be used for validation. Bracketing or matrix approach may be considered for validation of the same container/closure configuration for different products where process equivalence is scientifically justified.

iii. Maximum permitted holding times for sterile product and equipment exposed during the aseptic process.

iv. The volume filled per container, which should be sufficient to ensure that the media contacts all equipment and component surfaces that may directly contaminate the sterile product. The volume used should provide sufficient headspace to support potential microbial growth and ensure that turbidity can be detected during inspection.

v. The requirement for substitution of any inert gas used in the routine aseptic manufacturing process by air unless anaerobic simulation is intended. In these situations, inclusion of occasional anaerobic simulations as part of the overall validation strategy should be considered (see paragraph 9.33 point iii).

vi. The selected nutrient media should be capable of growing a designated group of reference microorganisms as described by the relevant pharmacopeia and suitably representative local isolates.

vii. The method of detection of microbial contamination should be scientifically justified to ensure that contamination is reliably detected.

viii. The process simulation should be of sufficient duration to challenge the process, the operators that perform interventions, shift changes and the capability of the processing environment to provide appropriate conditions for the manufacture of a sterile product.

ix. Where the manufacturer operates different or extended shifts, the APS should be designed to capture factors specific to those shifts that are assessed to pose a risk to product sterility, for example the maximum duration for which an operator may be present in the cleanroom.

x. Simulating normal aseptic manufacturing interruptions where the process is idle (e.g. shift changeovers, recharging dispensing vessels, introduction of additional equipment).

xi. Ensuring that environmental monitoring is conducted as required for routine production, and throughout the entire duration of the process simulation.

xii. Where campaign manufacturing occurs, such as in the use of Barrier Technologies or manufacture of sterile active substances, consideration should be given to designing and performing the process simulation so that it simulates the risks associated with both the beginning and the end of the campaign and demonstrating that the campaign duration does not pose any risk.

xiii. The performance of "end of production or campaign APS" may be used as additional assurance or investigative purposes; however, their use should be justified in the CCS and should not replace routine APS. If used, it should be demonstrated that any residual product does not negatively impact the recovery of any potential microbial contamination.

본문은 원문(영어)입니다. 국문 번역은 준비 중입니다.

출처: European Commission, DG SANTE · © European Union. Reuse is authorised provided the source is acknowledged (Commission Decision 2011/833/EU on the reuse of Commission documents). · 수집일 2026-11-15

Weekly Newsletter

이런 지적, 매주 월요일 한국어로 받아보세요

FDA·EMA·식약처의 새 지적과 조치를 공식 원문 링크와 함께 보내드립니다. 사이트에 새로운 기능이 생기면 함께 안내드립니다. 구독은 언제든 한 번의 클릭으로 해지할 수 있습니다.

이번 주 소식 먼저 보기

매주 월요일 발송 · 구독 신청 시 확인 메일이 발송됩니다 · 수신거부는 모든 메일 하단에서 가능합니다.